Table 1 Clinicopathological characteristics of patient samples and expression of transducin (β)-like 1 X-linked receptor 1 in breast cancer
Number of cases (%) | |
|---|---|
Gender | |
Male | 0 (0.0) |
Female | 214 (100.0) |
Age, years | |
≤47 | 101 (47.2) |
>47 | 113 (52.8) |
Clinical stage | |
I | 21 (9.8) |
II | 107 (50.0) |
III | 66 (30.8) |
IV | 20 (9.3) |
Tumor (T) classification | |
T1 | 69 (32.3) |
T2 | 113 (52.8) |
T3 | 24 (11.2) |
T4 | 8 (3.7) |
Node (N) classification | |
N0 | 67 (31.3) |
N1 | 80 (37.4) |
N2 | 63 (29.4) |
N3 | 4 (1.9) |
Metastasis (M) classification | |
No | 192 (89.7) |
Yes | 22 (10.3) |
Vital status at follow up | |
Alive | 146 (68.2) |
Dead | 68 (31.8) |
Histological differentiation | |
Well-differentiated | 8 (3.7) |
Moderately differentiated | 152 (71.0) |
Poorly differentiated | 54 (25.3) |
Expression of transducin (β)-like 1 X-linked receptor 1 | |
Low expression | 103 (48.1) |
High expression | 111 (51.9) |
Detectable | 214 (100.0) |
Undetectable | 0 (0.0) |
Expression of estrogen receptor | |
0 | 91 (42.6) |
1 | 98 (45.8) |
2 | 14 (6.5) |
3 | 11 (5.1) |
Expression of progesterone receptor | |
0 | 76 (35.5) |
1 | 99 (46.3) |
2 | 27 (12.6) |
3 | 11 (5.1) |
4 | 1 (0.5) |
Expression of c-erbB2 | |
0 | 36 (16.8) |
1 | 33 (15.4) |
2 | 29 (13.6) |
3 | 14 (6.5) |
4 | 3 (1.4) |